GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- B6515 WB 4101 hydrochlorideSummary: α1A-adrenergic antagonist
- B6516 ZaprinastSummary: phosphodiesterase inhibitor and GPR35 agonist
- B6528 1-Phenylbiguanide hydrochlorideSummary: 5-HT3 receptor agonist
- B6539 PindololSummary: β-adrenoceptor antagonist with partial agonist activity
- B6540 Spiperone hydrochlorideSummary: 5-HT2A serotonin and selective D2-like dopamine receptor antagonist
- B6580 SenktideSummary: NK3 tachykinin receptor agonist
- B6608 (R)-(-)-Niguldipine hydrochlorideSummary: L-type Ca2+ channel blocker and α1A-adrenoceptor antagonist
- B6624 Galanin (1-30) (human)Summary: Endogenous peptide with multiple endocrine, metabolic and behavioral effects
- B6625 PACAP 1-38Summary: Endogenous neuropeptide
- B6626 BQ-123Summary: Selective ETA receptor antagonist